Blueprint Medicines Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
The Massachusetts-based biotech’s fundraise will be used to discover and develop molecular glues with an initial focus on cancer targets.
Frazier Life Sciences managing partner James Topper described how the firm will use its 11th fund to launch new companies, support growing firms and take advantage of public market opportunities.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Bridge Biotherapeutics' CEO talks to Scrip about plans for autotaxin inhibitor returned by Boehringer Ingelheim in 2020, as well as other major R&D developments and priorities for this year and beyond.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.